ANVS News & Events

The deal priced below last closing price of $1.94. Canaccord is acting as sole book running manager for the offering.

Major indices fell for the third straight day, with the absence of any signs toward a resolution in the Strait of Hormuz standoff sustaining inflationary fears.   Energy was among the best performing sectors in the S&P 500 on Tuesday as WTI Crude Oil topped $104 per barrel.  Investors also rotated into the defensive areas of the market with Health Care, Consumer Staples and Utilities outperforming at the expense of Basic Materials and large-cap tech.  Global bond market rout also continued to impact sentiment, with Treasury yields rising at the medium and long end of the curve - of note, the 10-year to 3-month Treasury yield spread topped 100 basis points for the first time since 2022.In the opening hour of the evening session S&P 500 mini and NQ100 contracts are both down marginally.  In commodities, metals are being pressured by more pronounced strengthening in U.S. dollar - gold is below $4,500 and silver has fallen below $75 per ounce.   While the earnings season has largely concluded, results out of Nvidiatomorrow evening will dominate market debate on the health of the AI capex boomagainst the backdrop of higher funding costs over the next 24 hours.  The stock has fallen about 7% from last week's all-time high, though shares are still up nearly 20% year-to-date.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Red Robin Gourmet Burgersup 17.7%8x8, Inc.up 14.1%Cava Groupup 6.3%Keysight Technologiesup 3.8%Toll Brothersup 2.3%ALSO HIGHER -Robloxup 3.9% on $3B buyback announcementLeonardo DRSup 3.2% after insider buyDOWN AFTER EARNINGS -James Hardie Industriesdown 4.4%ALSO LOWER -Annovis Biodown 18.1% after equity offeringViavi Solutionsdown 6.3% after equity offering

Annovis Bio announced a proposed underwritten public offering in which it intends to offer and sell (i) shares of its common stock and (ii) accompanying warrants to purchase shares of common stock. The shares of common stock and the accompanying warrants will be issued separately but can only be purchased together in the proposed offering. All of the shares of common stock and the accompanying warrants will be offered by Annovis. Annovis intends to use the net proceeds from the offering for the continued clinical development of its lead compound buntanetap in a Phase 3 study for Alzheimer's disease (AD), and for working capital and general corporate purposes. Canaccord Genuity is acting as the sole bookrunner in the offering.